This paper presents a reflection based on 15 years' experience of stud
ies on the pharmacology of medicinal plants in an underdeveloped count
ry, Brazil. In these countries the investment in research is small and
frequently interrupted. There is no new-medicines development program
. Brazilian pharmaceutical companies have been short-sighted and have
not developed new drugs. Although the diversity of the Brazilian flora
is a remarkable opportunity for the development of new medicine produ
cts, natural product research is limited to a small group. These diffi
culties are common to all underdeveloped countries. Strategies for the
pharmacological study of medicinal plants are proposed, the main diff
iculties are identified and a discussion of possible ways to overcome
them is presented.